Abstract
Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse. At the time of relapse, the use of alternative drugs to those given upfront is current practice. However, many new options are currently available for the treatment of relapsed multiple myeloma, including recently approved drugs, such as the second- and third-generation proteasome inhibitors (carfilzomib and ixazomib), the second- and third-generation immunomodulatory drugs (lenalidomide and pomalidomide), the monoclonal antibodies (daratumumab and elotuzumab) and the histone deacetylase inhibitor (panobinostat). We here describe new treatment options for relapsed multiple myeloma in Poland based on drugs that can be used as part of the Ministry of Health's drug program in the context of ESMO guidelines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
